Risk Minimisation Materials

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

Yervoy (ipilimumab) Healthcare Professional Digital Risk Minimisation Material Platform

The Healthcare Professional (HCP) Platform is based on the UK ipilimumab paper based HCP risk minimisation materials

For Healthcare Professionals

Yervoy (ipilimumab) Patient Alert Card - Printable Version

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

Yervoy (ipilimumab) Patient Alert Card – Read Only Version

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

Yervoy (ipilimumab) Patient Digital Risk Minimisation Material Platform

The Patient Platform is based on the UK ipilimumab paper based Patient risk minimisation materials

Yervoy (ipilimumab) Patient Information Guide

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information.

Yervoy (ipilimumab) Risk Minimisation Information for Healthcare Professionals Guide for Prescribing

This risk minimisation material is a condition of the marketing authorisation. If you would like a hard copy of the Yervoy (ipilimumab) risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; e-mail: medical.information@bms.com) with your specific request.

For Healthcare Professionals